Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axis Capital

94.59
-0.3600-0.38%
Post-market: 94.590.00000.00%16:07 EDT
Volume:264.89K
Turnover:25.11M
Market Cap:7.44B
PE:7.66
High:96.04
Open:94.91
Low:93.78
Close:94.95
Loading ...

AXIS Capital Initiated at Market Perform by BMO Capital

Dow Jones
·
13 Jan

Axis Capital initiated with a Market Perform at BMO Capital

TIPRANKS
·
13 Jan

Axis Capital: Balancing Strong 2024 Performance with Cautious Optimism Amid Market Challenges

TIPRANKS
·
13 Jan

Axis Capital price target raised to $110 from $108 at Keefe Bruyette

TIPRANKS
·
11 Jan

AXIS Capital Is Maintained at Outperform by Keefe, Bruyette & Woods

Dow Jones
·
10 Jan

UBS Lifts Price Target on Axis Capital to $105 From $98, Keeps Buy Rating

MT Newswires Live
·
08 Jan

AXIS Capital Holdings Ltd : UBS Raises Target Price to $105 From $98

THOMSON REUTERS
·
08 Jan

AXIS Capital to Release Fourth Quarter Financial Results on January 29, 2025

Business Wire
·
07 Jan

Sara Farrup Becomes AXIS Head of Global Markets

Business Wire
·
06 Jan

AXS Rallies 58.5% in a Year: A Signal for Investors to Hold Tight?

Zacks
·
03 Jan

FAF Rises 17% in 6 Months: Time to Buy the Stock for Solid Returns?

Zacks
·
02 Jan

Truist says ‘aggressive’ buying Axsome Therapeutics after AXS-05 ADA data

TIPRANKS
·
31 Dec 2024

Buy Rating for Axsome Therapeutics: Promising AXS-05 Efficacy in Alzheimer’s Agitation

TIPRANKS
·
31 Dec 2024

Morgan Stanley still ‘positively inclined’ on Axsome Therapeutics’ AXS-05

TIPRANKS
·
31 Dec 2024

Axsome Therapeutics: Buy Rating Affirmed Amid Promising Trial Outcomes and Path Forward for AXS-05

TIPRANKS
·
31 Dec 2024

Positive Outlook for Axsome Therapeutics: AXS-05 Advances Despite Setbacks

TIPRANKS
·
31 Dec 2024

Buy Recommendation on Axsome Therapeutics: Strong Phase 3 Results for AXS-05 in Alzheimer’s Disease Agitation

TIPRANKS
·
30 Dec 2024

Axsome AXS-05 results in ADA ‘positive,’ drug looks ‘approvable,’ says Truist

TIPRANKS
·
30 Dec 2024

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

GlobeNewswire
·
30 Dec 2024

Here's Why Axis Capital (AXS) is a Strong Value Stock

Zacks
·
26 Dec 2024